

10/529314

JC17 Rec'd PCT/PTO 25 MAR 2005

Amendments to the Claims

The listing of claims below is intended to replace all prior listings of the claims:

1. (original) A composition comprising a caspase inhibitor and a non-caspase inhibitor anti-cancer agent.
2. (original) The composition of claim 1, wherein the caspase inhibitor is a pan caspase inhibitor.
3. (currently amended) The composition of claim 2, wherein the caspase inhibitor is selected from the group consisting of inhibitors of caspase-9 ~~caspase-9~~, caspase-3, caspase-8 or pan-caspase inhibitors.
4. (original) The composition of claim 1, wherein the caspase inhibitor inhibits the production of a caspase.
5. (original) The composition of claim 1, wherein the caspase inhibitor inhibits the activation of a caspase.
6. (original) The composition of claim 1, wherein the caspase inhibitor inhibits a signaling pathway of a caspase.
7. (currently amended) The composition of claim 1 ~~1-7~~, wherein the non-caspase anti-cancer agent is selected from the group consisting of alkylating agents, DNA strand breaking agents, antimetabolites, topoisomerase inhibitors, tubulin interactive agents, and mitotic inhibitors.
8. (currently amended) The composition of claim 1 ~~1-7~~, wherein the non-caspase inhibitor anti-cancer agent is BCNU.
9. (currently amended) The composition of claim 1 ~~1-7~~, further comprising an antioxidant.
10. (currently amended) The composition of claim 1 ~~1-7~~, wherein the anti-cancer agent is itself an antioxidant.
11. (currently amended) The composition of claims 10 ~~10-11~~, wherein the antioxidant is vitamin C or a glutathione pro-drug.

12. (currently amended) The composition of claim 1 ~~1-12~~, further comprising a pharmaceutical carrier.

13. (currently amended) A method of inhibiting the growth of a cancer cell comprising introducing the composition of claim 1 ~~claims 1-13~~ to the cell.

14. (currently amended) The method of claim 13 ~~14~~, wherein the cancer cell is killed.

15. (currently amended) A method of treating a subject having cancer comprising administering the composition of claim 12 ~~13~~ to the subject.

16. (original) A method of inhibiting the growth of a cancer cell comprising introducing a caspase inhibitor to the cell.

17. (currently amended) The method of claim 16 ~~17~~, wherein the cancer cell is killed.

18. (original) A method of treating a subject having cancer comprising administering a caspase inhibitor in a pharmaceutically acceptable form to the subject.

19. (currently amended) The method of claim 18 ~~claims 17-19~~, wherein the caspase inhibitor is a pan caspase inhibitor.

20. (currently amended) The method of claim 18 ~~claims 17-19~~, wherein the caspase inhibitor is specific for caspase-3, caspase-8 or caspase-9.

21. (currently amended) The method of claim 18 ~~claims 17-19~~, wherein the caspase inhibitor inhibits the production of a caspase.

22. (currently amended) The method of claim 18 ~~claims 17-19~~, wherein the caspase inhibitor inhibits the activation of a caspase.

23. (currently amended) The method of claim 18 ~~claims 17-19~~, wherein the caspase inhibitor inhibits a signaling pathway of a caspase.

24. (original) A composition comprising a caspase inhibitor and an antioxidant.

25. (currently amended) The composition of claim 24 ~~26~~, wherein the caspase inhibitor is a pan caspase inhibitor.

26. (currently amended) The composition of claim 24 ~~26~~, wherein the caspase inhibitor is specific for a caspase selected from the group consisting of caspase-3, caspase-8 or caspase-9.

27. (currently amended) The composition of claim 24 ~~26~~, wherein the caspase inhibitor inhibits the production of a caspase.

28. (currently amended) The composition of claim 24 ~~26~~, wherein the caspase inhibitor inhibits the activation of a caspase.

29. (currently amended) The composition of claim 24 ~~26~~, wherein the caspase inhibitor inhibits a signaling pathway of a caspase.

30. (currently amended) The composition of claim 24 ~~26-32~~, wherein antioxidant is selected from the group consisting of non-flavonoid antioxidants, multi-carotenes, beta-carotenes, alpha- carotenes, gamma-carotenes, lycopene, lutein and zeaxanthins, selenium, Vitamin E, tocopherol, vitamin E succinate, trolox, Vitamin C, Niacin, Vitamin A, 13-cis retinoic acid, N-acetyl-L-cysteine, glutathione pro-drugs, sodium ascorbate, pyrrolidinedithiocarbamate, coenzyme Q10, ~~Q10~~; peroxidases, glutathione peroxidase, catalase, superoxide ~~dismutase~~, ~~dismutase~~; glutathione transferase, glutathione reductase, glucose 6-phosphate dehydrogenase, glutathione, ~~glutathione~~; ceruloplasmin, cysteine, cysteamine, flavonoids, and ~~flavonoids~~, and mimetics, analogs and polymers thereof.

31. (currently amended) The composition of claim 24 ~~26-32~~, wherein the antioxidant is vitamin ~~C~~, C.

32. (currently amended) The composition of claim 1 ~~claims 1-7~~, further comprising a non-caspase anticancer agent.

33. (canceled)

34. (currently amended) The composition of claim 24 ~~26-36~~, further comprising a pharmaceutical carrier.

35. (currently amended) A method of inhibiting the growth of a cancer cell comprising introducing the composition of claim 24 ~~claims 26-37~~ to the cell.

36. (currently amended) The method of claim 35 ~~38~~, wherein the cancer cell is killed.

37. (currently amended) A method of treating a subject having cancer comprising administering the composition of claim 34 ~~38~~ to the subject.